Zevra Therapeutics resubmits Orphazyme asset to FDA
Zevra Therapeutics has been working to convince the FDA of arimoclomol’s benefits for years. Now the biotech company will see if it has been sucessful.
Zevra Therapeutics believes that it has now completed Orphazyme’s work. Therefore, after several postponements, the American biotech company has submitted the final re-application for marketing authorization for Orphazyme’s former crown jewel, arimoclomol.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
